Public trust in pharma has increased by just 12% post pandemic, reveals survey
March 2022 - Pharmaceutical
Public trust in pharma has increased by just 12% post pandemic: A survey has revealed that despite the high-profile role pharmaceutical companies have played during the Covid-19 pandemic, trust in them has increased by just 12%, compared to before the pandemic.
The Health and Life Sciences Experience Survey by Accenture polled around 1,200 people in the UK with a view to looking at how healthcare is changing.
It found that despite some pharmaceutical companies gaining greater brand recognition due to their role in developing Covid-19 vaccines, just a third of respondents (33%) said they would trust pharma companies with their health data.
When it comes to the levels of trust the public has in pharmaceutical companies, the research found that 43% of UK respondents polled would be more trusting if companies showed greater transparency in research and development. This compared to 36% who said the same globally.
More than two-fifths (41%) said that trust could be improved through clearer communication about medications and treatments (how effective they are, as well as any possible side effects), and through showing greater transparency on pricing (42%). This compares to 35% who said the same globally.
Medical data
Almost half the respondents polled (47%) said that they would permit their personal health data to be shared with pharmaceutical companies if it led to improved health outcomes and treatment. The same percentage (47%) also said that they would allow their data to be shared if it helped further the developments of new medications and treatments.
Just 20% of respondents said they would allow a pharmaceutical company to manage a chronic illness in collaboration with a medical provider. Furthermore, just 62% of patients with a chronic illness said that they had considered taking part in a clinical trial to access new treatments and medicines. Almost half the respondents polled (47%) said they would not take part in clinical trials due to ‘health concerns’, while a third (32%) said that a ‘lack of awareness’ was a barrier to taking part.
Sign up to our newsletter to receive free insights from your sector...
Support Us...
We hope that you have found this article useful. This section is freely available for all to use. Please help support it by liking us or following us on our social media platforms:
